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Julie Robinson, Merzaka Derradji, Chhaya Pandit, Anuja Batugedara, Tariq 
Mahmood 
 
Abstract 
 
The aim of this naturalistic survey was to measure the prevalence of metabolic 
syndrome by collating data on routine physical investigation in an acute psychiatric 
inpatient population. The size of this study is small, but the results offer some 
interesting and useful preliminary findings, pertinent to the provision of good 
physical health care to psychiatric inpatients and from which further research could 
develop. 
 
Metabolic syndrome was found in more than a third (38%) of the population studied 
and was equally prevalent across a variety of psychiatric disorders.  A higher trend 
was found in females than in males, but this figure did not reach statistical 
significance.  Although small, the naturalistic setting of this survey demonstrates the 
ease with which metabolic syndrome can be opportunely excluded or identified in 
this vulnerable population, where physical healthcare is often problematic.  With the 
increasing involvement of non-medically qualified practitioners in psychiatric care, 
simple techniques such as this hold a valuable place in holistic patient management. 
 
Key words: Survey, Metabolic Syndrome, Physical Health, Inpatients, 
Antipsychotics 
 
Introduction 
 
Those with schizophrenia and other major mental illnesses have been found to be 
physically less fit than the general population (Newman and Bland, 1991), with an 
increased risk of cardiovascular morbidity and mortality (Brown 1997; Casey 2005). 
In most cases, the origin of this increased risk is multi-factorial, including genetics, 
lifestyle factors and the regular use of psychotropic medication.  
 
With regard to the role of genetics, evidence suggests metabolic disturbance to be 
an inherent part of psychotic illness, rather than a consequence of treatment. Higher 
rates of abnormal glucose metabolism in schizophrenia were recognised prior to the 
introduction of antipsychotics in the 1960’s and Mukherjee et al (1989) found rates 
of type 2 diabetes mellitus in family members of schizophrenics  to be between 19 
and 31% - exceeding that found in the background population. In a more recent 
review, medication free first episode schizophrenics were found to have already 
increased rates of obesity and impaired fasting glucose metabolism (Thakore, 
2004). Smoking, inadequate physical activity, poor diet and concomitant drug and 
alcohol use are some of the significant lifestyle factors seen in schizophrenia which 
impact upon cardiovascular health. 
  
Metabolic Syndrome 
 
Metabolic syndrome, a cluster of signs and symptoms, has been found to have a 
correlation with increased cardiovascular risk. Whilst prevalence of the syndrome in 
non-psychiatric populations ranges between 6 and 11% (Saari et al, 2005; Mackin et 
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al, 2007) estimates of its prevalence have been found to be high (up to 54%) in 
community samples of psychiatric patients on regular antipsychotic medication. 
(Mackin et al, 2007; Lamberti et al, 2006; Morgan et al, 2008) Originally 
operationally defined in 2002 by the National Cholesterol Education Programme 
(NCEP) the definition of metabolic syndrome was adapted in 2005 by the 
International Diabetes Federation (IDF, 2005) - it is this latter and most recent 
definition which we use in our survey. 
 
Figure 1 – 2005 IDF Criteria for Metabolic Syndrome 
 
Metabolic syndrome is defined as -  
 
1. Abdominal obesity measured as waist circumference more than or equal to  
 94cm in men and 80cmin women 
 
Plus two or more of the following 
 
2. Raised triglycerides (TG) more than or equal to 1.7mmol/L* 
 
3. Reduced high density lipoprotein (HDL) cholesterol less than or equal to 
 1.0mmol/L in men and 1.3mmol/ in women* 
 
4. Raised blood pressure more than or equal to 130/85mmHg* 
 
5. Raised fasting blood glucose level (BGL) more than 6.1mmol/L 
 
* or on treatment for this. 
 
(IDF, 2005) 
 
 Metabolic Syndrome and Medication 
 
Since their widespread introduction, second generation (atypical) antipsychotic 
agents (clozapine, olanzapine, amisulpiride, quetiepine, aripiprazole, zotepine and 
risperidone) have been promoted for use in schizophrenia.  Whilst favourably 
associated with fewer neurological side effects, concerns remain regarding their 
potential to adversely affect metabolism, and thus research around medication and 
metabolic syndrome focuses on the role of first (typical) and second generation 
antipsychotics, rather than other medication. 
 
Strong evidence exists for the association between antipsychotics and metabolic 
syndrome. In a large community based matched case-control study of severely 
mentally ill on (or recently on) anti-psychotics (Mackin et al 2007) found the case 
group to have higher rates of metabolic syndrome than controls, irrespective of 
whether they were prescribed first or second generation antipsychotics. A further 
large study of inpatients receiving only second generation antipsychotics identified 
metabolic syndrome in 47% of the sample (Correll et al, 2006).  
  
A Dutch systematic review (Scheepers-Hoeks et al, 2008) investigating the 
differences in the metabolic effects of first and second generation antipsychotics 
summarises that although both groups appear to increase the risk of developing 
type 2 diabetes, it is the second generation ones which are more associated with 
obesity and dyslipidaemia. Comparison studies indicate that certain antipsychotics 
are more strongly associated with metabolic syndrome than others. In particular 
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olanzapine and clozapine (owing to their propensity for weight gain) are studied and 
evidence points to these two in particular being associated with a higher risk of 
developing the syndrome (Newcomer, 2007) with aripiprazole  having a much lower 
risk of adverse metabolic effects. (L’Italien et al, 2007), (Haupt, 2006). 
 
The National Institute for Clinical Excellence (NICE) (NICE Clinical Guideline 1, 
2006) and the National Service Framework (NSF) (Department of Health, 2007) 
recommend regular physical health monitoring for patients with severe and enduring 
mental illness. However, significant difficulties can be associated with the delivery of 
good and regular physical healthcare to this group. Variable engagement and 
compliance coupled with periods of acute mental ill health seen in chronic mental 
illness make education and physical health monitoring a challenge - and it remains 
unclear as to what is the best way to identify those at risk in terms of their physical 
health.   
 
We propose that psychiatric patients should be monitored for the presence of 
metabolic syndrome and an opportune time to do so is when they are hospitalised. 
Medical and psychosocial/educational interventions could be introduced during 
hospital admission. With this in mind we decided to investigate the prevalence of 
metabolic syndrome in acute psychiatric inpatients, in a naturalistic study design. As 
far as we know such a study has not been carried out before.  
 
Method 
 
Individuals admitted to 3 acute wards (2 male and 1 female) over a period of 4 
consecutive months were considered. All those able and willing to consent to the 
use of their data in the survey and who agreed to full physical assessment were 
asked. Written informed consent was obtained and this survey was approved by the 
Leeds East Research Ethics Committee. A full physical examination including blood 
tests is considered a minimum requirement as part of the assessment of any new 
patient to the ward. Waist circumference is not normally recorded as part of the 
physical examination – this was an additional measurement to the usual 
examination. 
 
Data were collected and recorded by the researchers on all those who consented. In 
addition to the criteria for metabolic syndrome (waist circumference, triglycerides, 
HDL (high density lipoprotein) cholesterol, blood pressure and fasting blood glucose 
level), the following was documented for each individual – age, gender, ethnicity, 
diagnosis and current medication. Chi squared was used as the test of statistical 
significance for the analysis of the categorical group data calculated from the 
recording of the metabolic syndrome criteria parameters. The Chi squared test was 
applied to look for significant differences between numbers where the syndrome 
was present versus absent and also in males versus females in the group where it 
was present.  
 
Results 
 
In total 14 females and 26 males were included. A small number (5) were deemed 
not capacitous or declined to be included in the study. The characteristics of the 
sample are displayed in Table 1. The sample included inpatients with a variety of 
psychiatric diagnoses. Men outnumbered women 1.9:1 and with regards to ethnicity, 
the sample was predominantly white and Asian. 
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Table 1- Characteristics of Sample 
 
                                                             Male                           Female 
 
N                                                                26                                        14 
 
Mean age (range)             42.3 (18-62)                  41.7 (17-63) 
 
Ethnicity 
White       17          13 
Black        1           1 
Asian         8           0 
 
ICD-10 Diagnosis 
 
Psychosis                14           3 
Paranoid schizophrenia F20.0   6           2   
Delusional disorder F22.0   2           1   
Acute schizophrenia-like 
psychotic disorder F23.2   6           0  
 
Affective                11           7 
Bipolar affective disorder, current 
episode severe depression F31.4, F31.5  2           1 
Bipolar affective disorder, current  
episode manic F31.1, F31.2   3           3 
Severe depressive episode F32.2, F32.3 6           3  
 
Other       1           4 
Alcohol withdrawal state F10.3   1           0 
Emotionally unstable personality 
disorder – borderline type F60.31   0           2 
Obsessive compulsive disorder F42.2        0           1 
Organic hallucinosis F06.0    0           1 
 
More than one third of our patients (38%) met the criteria for metabolic syndrome. 
(Table 2) Relatively more women than men had metabolic syndrome – however the 
trend did not reach statistical significance (χ2  2.61 df 1 p > 0.1). There was no 
difference in the occurrence of metabolic syndrome when comparing psychotic 
illnesses (schizophrenia, delusional disorder and acute schizophrenia-like psychotic 
disorder) with affective illness (bipolar affective disorder and depression). 
Prevalence of Metabolic Syndrome in Psychiatric Inpatients: 
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Table 2 – Numbers Meeting Criteria for Metabolic Syndrome According to 
Gender and Diagnosis 
 
 
                                       Present n (%)          Absent n (%) 
Psychiatric                                15 (38)                         25 (62)            
Inpatients 
 
Male                                           8 (31)                          18 (69)             
 
Female                                      7 (50)                            7 (50)              
 
ICD-10 Diagnosis 
Psychotic            7 (41)                  10 (59) 
Paranoid schizophrenia               3             5 
Delusional Disorder               3                         0 
Acute schizophrenia-like  
psychotic disorder               1              5 
 
Affective           7 (39)                 11 (61) 
Bipolar affective disorder, 
current episode severe  
depression                3                                 0 
Bipolar affective disorder, 
current episode manic               2              4 
Severe depressive episode         2                                 7 
Other             1 (20)                   4 (80) 
Alcohol withdrawal state              0                                  1 
Emotionally unstable personality  
disorder- borderline type              0                                  2 
Obsessive compulsive  
disorder                0                                   1 
Organic hallucinosis                    1               0 
 
Further analysis of the data (focusing on antipsychotic prescription) showed that 9 of 
the group of 15 (60%) with metabolic syndrome were prescribed antipsychotic 
medication (Table 3).  In 2 cases this was in combination with a second 
antipsychotic, and in 6 cases it was a sole second generation agent.  Interestingly, 
18 of the sample who were on antipsychotic medication did not fit the criteria for 
metabolic syndrome and 12 of this group were on second generation antipsychotics.  
The range of antipsychotics prescribed was wide and so inferences on specific 
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medications such as olanzapine and clozapine could not be made. Of the 4 
participants who were prescribed aripiprazole 3 did not have metabolic syndrome. 
 
Table 3 – Number of Participants Prescribed Antipsychotics  
                                                       Metabolic Syndrome  
                                                   Present                      Absent 
                                                        n                              n 
 
On antipsychotic   9   18   
Not on antipsychotic   6    7 
 
Single antipsychotic   7   18 
 
Combination antipsychotic  2   0 
 
 
 
Discussion 
 
Significant Findings 
 
• We found a high rate (38%) of metabolic syndrome in psychiatric inpatients. This 
figure is in keeping with the findings of previous surveys, ranging from 30% - 
54%, in community psychiatric populations (Mackin et al, 2007; Lamberti et al, 
2006; Morgan et al, 2008) and up to 47% in hospitalised patients. (Correll et al, 
2006) In contrast, an extensive Finnish birth cohort study estimated the 
prevalence of metabolic syndrome in a non-psychiatric population to be only 6%, 
demonstrating the significance of psychiatric illness on physical health 
parameters. (Saari et al, 2005)  
 
Morgan’s survey, also looking at psychiatric inpatients, detected a much lower 
rate (11%) than did our study. (Morgan et al, 2008). Although carried out on an 
inpatient population, this work is not directly comparable to ours as the sample 
were all long stay inpatients and treated with clozapine. The surprisingly low rate 
of metabolic syndrome in Morgan’s study (given clozapine’s widely 
acknowledged side effect of weight gain) could be due to those patients being 
more carefully physically monitored than they might have been in a more 
independent community setting – as a result of being long stay inpatients, staff 
can easily access this group to ensure good physical healthcare, also demanded 
by the clozaril patient monitoring service. 
 
• We found a higher trend, which did not reach statistical significance, amongst 
female psychiatric inpatients. This trend has been reported elsewhere in similar 
studies. (Lamberti et al, 2006), (Morgan et al, 2008)  
 
• The data for individual diagnoses was too small to be analysed in detail. 
However, no major difference in the figures for metabolic syndrome existed 
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when comparing those diagnoses considered under the broad heading of 
psychoses (schizophrenia, delusional disorder, acute schizophrenia-like 
psychotic disorder) and those under an affective heading (bipolar affective 
disorder and depression). This pattern of metabolic syndrome existing across a 
wide range of psychiatric diagnoses has been reported elsewhere.  (Mackin et 
al, 2007; Correl et al, 2006). In our study, this widespread occurrence may be a 
consequence of the broad use of antipsychotics, not only for those with 
psychotic illness, but also for those with affective illness in its most severe form 
(for example requiring treatment for psychotic symptoms and high states of 
arousal). 
 
• Metabolic syndrome existed in 9 out of 15 of those who were taking 
antipsychotics, all of whom were prescribed at least one second generation 
antipsychotic. This is in keeping with the findings cited earlier regarding the 
association between second generation antipsychotics and metabolic syndrome.  
 
What was surprising was our finding of 18 other participants, also on 
antipsychotic treatment, who did not have metabolic syndrome, 12 of whom 
were on second generation antipsychotic medication. We did not collect 
information on past antipsychotic treatment or current doses for our study – it 
may be that this group had only been very recently prescribed their medication 
or that the doses were low and hence had not yet influenced metabolism in any 
way.  
 
Patients with mental illness, treated with antipsychotics and admitted to the 
inpatient wards via the current mode of service delivery are by definition high 
risk, and hence demand enhanced and consistent care not only when 
hospitalised, but when in the community too. Another explanation for the above 
finding is that this potentially risky group is being well and regularly monitored, 
including good advice on lifestyle factors, in terms of both their physical and 
mental health, with the resulting effect that they have not developed metabolic 
syndrome. A further explanation (bearing in mind the strength of evidence for the 
role of antipsychotics in metabolic syndrome) is that this patient group are not 
fully medication compliant.  
 
In our sample only 4 were prescribed aripirazole – a second generation 
antipsychotic associated with being less likely to cause adverse metabolic 
effects. (L’Italien, 2007), (Haupt 2006). Only one of this group on aripirazole 
fitted the criteria for metabolic syndrome. 
  
Clinical Relevance for Psychiatry 
 
This survey has identified 38% of a sample of the local mental health service’s most 
unwell and arguably most vulnerable service users to be at increased risk of 
cardiovascular disease, as predicted by the presence of the metabolic syndrome. 
Metabolic syndrome has its critics  (Gale, 2008) but we propose that the simple, 
quick detection of risk factors is valuable in such patient groups.  
 
Opportune detection of physical ill health indicators is important in the severely 
mentally unwell where physical health care and monitoring can be problematic. With 
the increased involvement in mental health of non-medically qualified practitioners, 
simplification which aids the understanding of physical health problems, for both 
care co-ordinators and patients, may prove to be helpful in achieving satisfactory, 
holistic management. Without a method such as this to easily detect important 
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physical health risks, how can this patient group be well cared for and offered 
appropriate treatment and advice to improve their physical (and mental) well being? 
 
In special populations, where physical healthcare is even more problematic, such as 
those with learning disability or where other barriers to good physical healthcare 
from primary care exist, diagnosis of metabolic syndrome on contact with mental 
health services, and then as a tool for monitoring, has already been proposed. 
(Thakore, 2005) The naturalistic setting of this survey demonstrates the ease with 
which such a strategy can be implemented in an inpatient population. 
 
Implications for General Practice and Public Health 
 
The implementation of the National Service Framework for Mental Health in 1999, 
with the introduction of shared care, identifies general practitioners as responsible 
for the regular review of the physical healthcare of psychiatric patients. This is 
reflected in current NICE guidance for schizophrenia. (NICE Clinical Guideline 1, 
2006) The presence or absence of metabolic syndrome, as a clear and definitive 
finding, can be easily communicated to and then acted upon by primary care 
practitioners. It also offers a method by which the baseline parameters can be 
monitored over time. 
 
Limitations of this Study 
 
The study provides an estimate of the prevalence of metabolic syndrome in 
psychiatric inpatients. The sample, however, was without a control group and 
relatively small and hence further statistical inferences about the relationship 
between medication (including medications other than antipsychotics), age or 
diagnosis with metabolic syndrome cannot be drawn. This is limited also by there 
having been no data collected on previous antipsychotic treatment or past medical 
history. 
 
Conclusions 
 
Our original aim was to measure the prevalence of metabolic syndrome in an acute 
psychiatric inpatient population and we detected a high rate of 38% in our sample.  
Our hope was that our findings could be used to inform the delivery of good patient 
care.  The clinical relevance of this study’s findings is high – a positive detection of 
metabolic syndrome provides a baseline from which to monitor and treat any 
emerging (and potentially life-threatening) cardiovascular problems. We have also 
demonstrated that measuring the criteria for metabolic syndrome is quick, simple 
and inexpensive.  We therefore propose that the measurement of the metabolic 
syndrome parameters (including the recording of waist circumference) become 
routine for psychiatric inpatients. 
 
This work warrants being taken further and we suggest a useful project would be to 
repeat the study with a larger sample and a control.  An adequately sized 
comparison group from a general hospital setting matched for age, sex, ethnicity 
and socio-economic class status could be designed to investigate the association 
between both antipsychotic use and the presence of major mental illness with 
metabolic syndrome. The finding of metabolic syndrome as more frequent in women 
than in men also warrants special consideration and further study. Given that the 
responsibility for continuing physical healthcare lies in general practice, liaison with 
this part of the service regarding the communication and use of patient data on 
metabolic syndrome would be an essential step in any future work.  Ideally the 
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presence or absence of metabolic syndrome ought to be included clearly on hospital 
discharge summaries and Care Programme Approach documents – a standard 
which lends itself easily to future audit. 
 
We conclude that the measurement of metabolic syndrome is a useful and easily 
applicable way of identifying cardiovascular risk. Rates of metabolic syndrome in the 
psychiatric inpatient population are high and hospitalisation offers an opportune time 
to implement the criteria and therefore ought to be offered as a routine part of 
admission to hospital. 
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